MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Editas Medicine Company Profile (NASDAQ:EDIT)

Consensus Ratings for Editas Medicine (NASDAQ:EDIT) (?)
Ratings Breakdown: 3 Hold Rating(s), 2 Buy Rating(s)
Consensus Rating:Hold (Score: 2.40)
Consensus Price Target: $33.75 (29.46% upside)

Analysts' Ratings History for Editas Medicine (NASDAQ:EDIT)
Show:
DateFirmActionRatingPrice TargetActions
6/10/2016Jefferies GroupReiterated RatingHold$35.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/16/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/29/2016Morgan StanleyInitiated CoverageEqual -> Equal Weight$28.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/29/2016JPMorgan Chase & Co.Initiated CoverageNeutral$32.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/29/2016JMP SecuritiesInitiated CoverageOutperform$40.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/26/2014 forward)
Earnings History for Editas Medicine (NASDAQ:EDIT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
5/16/2016        
5/16/2016Q116($0.30)($0.80)$1.08 million$0.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/30/2016Q4($0.52)($4.05)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Editas Medicine (NASDAQ:EDIT)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($0.44)($0.44)($0.44)
Q3 20161($0.55)($0.55)($0.55)
Q4 20161($0.60)($0.60)($0.60)
(Data provided by Zacks Investment Research)
Dividend History for Editas Medicine (NASDAQ:EDIT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Editas Medicine (NASDAQ:EDIT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
2/8/2016James E FlynnInsiderBuy100,000$16.00$1,600,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Editas Medicine (NASDAQ:EDIT)
DateHeadline
06/24/16 12:28 PM​Another Mass. biotech plans to take the IPO plunge despite Brexit uncertainty -
06/23/16 02:43 PMCrispr Wins Key Approval to Fight Cancer in Human Trials
06/22/16 03:52 PMEditas Medicine Inc. (NASDAQ:EDIT) plummeted -7.04%: AT&T, Inc. (NYSE:T), Synergy Resources Corporation ... - KC Register
06/21/16 03:35 PMEditas Medicine Inc. (NASDAQ:EDIT) Dropped-5.14%: Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), Superior Energy ... - KC Register
06/20/16 09:58 AMGlobal Synthetic Biology Market is expected to Grow more than US$ 38 Billion by 2020 - by Market Research Engine
06/19/16 08:11 AMGlobal Synthetic Biology Market is expected to Grow more than US$ 38 Billion by 2020 – by Market Research Engine
06/18/16 08:19 AMEditas Medicine (NASDAQ:EDIT) decreased -3.78%: Valeant Pharmaceuticals Intl Inc (NYSE:VRX), Xcel Energy ... - KC Register
06/17/16 07:57 AM'Altered mosquito next malaria weapon', says Gates
06/16/16 09:00 PMGates Says Altered Mosquito Is Next Weapon to Fight Malaria (2)
06/16/16 08:06 AMDoes this company hold a key to unlock biotech's Goldilocks space dilemma?
06/16/16 08:06 AMTopsy-Turvy Day
06/06/16 07:06 AMBrokers Set Expectations for Editas Medicine Inc's Q2 2016 Earnings (EDIT) - Let Me Know About This
06/02/16 03:54 PMSynthetic Biology Market Share,Supply and Consumption Market Report to 2020 - Scientific genomics Inc. Editas Medicine, Inc., Pareto Biotechnologies, Blue heron, TeselaGen, Twist biosciences, Syntrox Inc., and others. This report provides an extensive analysis of the current and emerging market trends and dynamics in the world ...
06/02/16 08:05 AMTop Analyst Upgrades and Downgrades: Deutsche Bank, Editas, EMC, Exxon Mobil, First Solar, Newmont Mining and More -
05/28/16 11:20 AMEditas Medicine Incorporated (NASDAQ:EDIT) Shorted Shares Decreased By 1.66% - HNN - Editas Medicine Incorporated (NASDAQ:EDIT) Shorted Shares Decreased By 1.66%HNNEditas Medicine, Inc., formerly Gengine, Inc., is a genome editing company. The company has a market cap of $1.27 billion. The Firm is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It ...
05/25/16 04:39 PMEditas Medicine Inc (NASDAQ:EDIT) Stock Update & Estimates - Stock Tick Tock - Editas Medicine Inc (NASDAQ:EDIT) Stock Update & EstimatesStock Tick TockThe consensus on Wall Street is expecting Editas Medicine Inc (NASDAQ:EDIT) to post earnings of $-0.47 per share when the firm next reports it's fiscal quarterly results. According to the latest information available the report will likely be issued ...and more »
05/25/16 07:22 AMEditas Medicine, Inc. breached its 50 day moving average in a Bullish Manner : EDIT-US : May 25, 2016 -
05/24/16 04:43 PMEditas Medicine to Present at Upcoming June Investor Conferences - Virtual-Strategy Magazine - Editas Medicine to Present at Upcoming June Investor ConferencesVirtual-Strategy MagazineEditas Medicine is a leading genome editing company dedicated to treating patients with genetically-defined diseases by correcting their disease-causing genes. The Company was founded by world leaders in genome editing, and its mission is to translate ...
05/24/16 03:26 PMEditas Medicine to Present at Upcoming June Investor Conferences - [at noodls] - CAMBRIDGE, Mass., May 24, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will present company overviews at three upcoming investor ...
05/23/16 07:05 AM10 Speculative Biotech and BioHealth Stocks With Massive Analyst Upside Calls -
05/22/16 04:45 PMRevenue Update on Editas Medicine, Inc. - Common Stock(NASDAQ:EDIT) - Trade Calls - Trade CallsRevenue Update on Editas Medicine, Inc. - Common Stock(NASDAQ:EDIT)Trade CallsEditas Medicine, Inc. – Common Stock(NASDAQ:EDIT) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during Pre-market on May 16, 2016. Company reported revenue of $805.00K. Analysts estimated a revenue of $1.08M.and more »
05/20/16 12:04 PMEDITAS MEDICINE, INC. Financials -
05/17/16 04:47 PMEarnings Alert: Editas Medicine Inc (NASDAQ:EDIT) - The Point Review - The Point ReviewEarnings Alert: Editas Medicine Inc (NASDAQ:EDIT)The Point ReviewEditas Medicine Inc (NASDAQ:EDIT) shares traded during its most recent trading session in the range of $30.89 – $36.24. The stock has climbed 12.21% in the past week and plunged -14.72% in the last 4 weeks, historically the stock illustrate that its ...Janney Remains Bullish on Editas Medicine24/7 Wall St.Editas Medicine Announces Agreement with Cystic Fibrosis Foundation Therapeutics to Advance New CRISPR/Cas9 ...NasdaqEditas Medicine Signs Deal with Cystic Fibrosis Foundation Therapeutics to Treat CF; Shares Rise 6% Early (NASDAQ ...Sonoran Weekly ReviewGlobeNewswire (press release) -Benchmark Monitor -Risers & Fallersall 19 news articles »
05/16/16 04:33 PMBRIEF-Editas Medicine Q1 loss per share $0.80 - Reuters - BRIEF-Editas Medicine Q1 loss per share $0.80ReutersBRIEF-Editas Medicine Q1 loss per share $0.80. May 16 Editas Medicine Inc. * Editas medicine announces first quarter 2016 results and update. * Q1 loss per share $0.80 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: ...
05/16/16 04:33 PMJanney Remains Bullish on Editas Medicine - 24/7 Wall St. - 24/7 Wall St.Janney Remains Bullish on Editas Medicine24/7 Wall St.Editas Medicine Inc. (NASDAQ: EDIT) has become a rather interesting stock for many speculative biotech and biohealth investors. It has also been quite volatile. Its shares were trading higher on Monday after the release of its quarterly results and ...Editas Medicine Announces First Quarter 2016 Results and UpdateGlobeNewswire (press release)Editas Medicine Posts Wider Q1 Loss Vs. Street, Misses on Revenue (NASDAQ:EDIT)Sonoran Weekly ReviewEditas Medicine, Inc. (NASDAQ:EDIT) Expected To Report Earnings On MondayRisers & FallersFranklin Independent -Seeking Alpha -Boston Business Journal (blog)all 14 news articles »
05/16/16 03:12 PMEdited Transcript of EDIT earnings conference call or presentation 16-May-16 12:30pm GMT -
05/16/16 11:15 AMJanney Remains Bullish on Editas Medicine -
05/16/16 07:30 AMEditas Medicine Inc Earnings Call (Q1 2016) - Editas Medicine, Inc. operates as a genome editing company. It focuses on treating patients with genetically defined diseases by correcting their disease causing genes. It is developing a proprietary genome editing platform based on CRISPR/Cas9 technology ...
05/16/16 07:30 AMEDITAS MEDICINE, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) - On May 16, 2016, Editas Medicine, Inc., a Delaware corporation (the "Company"), issued a press release announcing financial results for the fiscal quarter ended March 31, 2016. A copy of the press release is being furnished as Exhibit 99.1 to this Current ...
05/16/16 07:19 AMEditas Medicine Inc Earnings Call scheduled for 8:30 am ET today -
05/16/16 06:47 AMEDITAS MEDICINE, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh -
05/16/16 06:42 AMEditas Medicine Announces First Quarter 2016 Results and Update - [at noodls] - Advancing pipeline and platform demonstrated by data presented at medical and scientific conferences as well as achievement of Juno Therapeutics milestone Strengthened effort to develop medicines for cystic ...
05/16/16 06:42 AMEditas Medicine Announces Agreement with Cystic Fibrosis Foundation Therapeutics to Advance New CRISPR/Cas9 Medicines - [at noodls] - CAMBRIDGE, Mass., May 16, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced a three-year agreement with Cystic Fibrosis Foundation Therapeutics, ...
05/16/16 06:07 AMQ1 2016 Editas Medicine Inc Earnings Release - Before Market Open -
05/13/16 03:17 PMEDITAS MEDICINE, INC. Files SEC form 10-Q, Quarterly Report -
05/13/16 07:19 AMThree Cambridge startups are on a mission to fix broken genes - Rival firms Editas Medicine Inc., Intellia Therapeutics Inc., and CRISPR Therapeutics are all pioneering an emerging technology known as gene editing. They use a new scientific tool called CRISPR-Cas9 that holds the promise of curing thousands of genetic ...
05/12/16 07:04 AMWill CRISPR Therapeutics go public like its rivals? - All three companies that have licensed the technology — Editas Medicine Inc., Intellia Therapeutics Inc., and CRISPR Therapeutics — have their R&D operations in Kendall Square, about a mile apart. Editas and Intellia have boomed since their initial ...
05/10/16 07:36 AMEditas Medicine to Host Conference Call Discussing First Quarter 2016 Corporate Update and Results - GlobeNewswire (press release) - Editas Medicine to Host Conference Call Discussing First Quarter 2016 Corporate Update and ResultsGlobeNewswire (press release)CAMBRIDGE, Mass., May 09, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Monday, May 16, 2016 at 8:30 a.m. ET to discuss a ...Editas Medicine Incorporated (NASDAQ:EDIT) Shorted Shares Increased By 40.98%B.O.D.Y Confidentialall 2 news articles »
05/09/16 07:00 AMEditas Medicine to Host Conference Call Discussing First Quarter 2016 Corporate Update and Results - [GlobeNewswire] - CAMBRIDGE, Mass., May 09, 2016-- Editas Medicine, Inc., a leading genome editing company, today announced that it will host a conference call and webcast on Monday, May 16, 2016 at 8:30 a.m. ET to discuss ...
05/08/16 01:06 PM5 Diseases That Could Be Cured in the Next Decade -
05/07/16 04:26 PMGene Editing Company Intellia Therapeutics Prices Their IPO At $18.00, The Top Of The Range - Dr. Doudra was a co-founder of competitor Editas Medicine, Inc. (EDIT: Nasdaq), who went public in February of this year. When a key CRISPR patent was granted to another Editas, co-founder, Feng Zhang, Dr. Doudra broke off to pursue her own patent with her ...
05/06/16 04:30 PMBiotech Stocks Are Down 25% So Far This Year -
05/06/16 05:50 AM​Gene editing firm Intellia raises $163M in largest biotech IPO of 2016 -
05/05/16 04:25 PMEditas Medicine Incorporated (NASDAQ:EDIT) Shorted Shares Increased By 40.98% - B.O.D.Y Confidential - Editas Medicine Incorporated (NASDAQ:EDIT) Shorted Shares Increased By 40.98%B.O.D.Y ConfidentialEditas Medicine, Inc., formerly Gengine, Inc., is a genome editing company. The company has a market cap of $1.14 billion. The Firm is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It ...
05/04/16 04:25 PMEditas Medicine Achieves Milestone under its Collaboration with Juno Therapeutics - GlobeNewswire (press release) - Editas Medicine Achieves Milestone under its Collaboration with Juno TherapeuticsGlobeNewswire (press release)CAMBRIDGE, Mass., May 04, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, announced today that it has achieved a $2.5 million milestone under its collaboration with Juno Therapeutics, Inc.Editas Medicine Hits $2.5 Mil. Milestone Payment from Juno Therapeutics Deal; Shares Edge Higher Pre Bell ...Sonoran Weekly ReviewIs Selling Editas Medicine Inc Here a Winning Strategy?Franklin Independentall 3 news articles »
05/04/16 06:40 AMEditas Medicine Achieves Milestone under its Collaboration with Juno Therapeutics - [at noodls] - CAMBRIDGE, Mass., May 04, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, announced today that it has achieved a $2.5 million milestone under its collaboration ...
05/04/16 06:31 AM7:31 am Editas Medicine achieves $2.5 mln milestone under a collaboration with Juno Therapeutics (JUNO) -
05/03/16 04:02 PMEditas Medicine and Radius Health Choose Mass Innovation Labs for Rapid Start and Operational Capabilities - Business Wire (press release) - Editas Medicine and Radius Health Choose Mass Innovation Labs for Rapid Start and Operational CapabilitiesBusiness Wire (press release)The latest member companies include Editas Medicine Inc., a leading genome editing company dedicated to treating patients with genetically defined diseases, and Radius Health, a science-driven biopharmaceutical company focused on developing new ...and more »
05/03/16 07:04 AMIntellia Therapeutics IPO: The “Biggest Biotech Discovery of the Century” - Besides, investors have been fairly receptive to Crispr-Cas9, as seen with the recent IPO of Editas Medicine Inc (EDIT). Since coming public in early February, the shares have racked up gains of about 106%. No doubt, this should bode well for the NTLA ...
05/02/16 07:54 AMEditas Medicine, Inc. breached its 50 day moving average in a Bearish Manner : EDIT-US : May 2, 2016 -
About Editas Medicine

Editas Medicine logoEditas Medicine, Inc., formerly Gengine, Inc., is a genome editing company. The Company is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) technology. CRISPR/Cas9 uses a protein ribonucleic acid (RNA) complex consisting of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence that requires repair. The Company has initiated a range of research programs across multiple therapeutic areas. Its programs include Eye Diseases, Engineered T Cell Therapies for Immuno-Oncology and additional research programs, including Non-malignant Hematologic Diseases, Duchenne Muscular Dystrophy, Cystic Fibrosis and Alpha-1 Antitrypsin Deficiency.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: EDIT
  • CUSIP:
Key Metrics:
  • Previous Close: $26.07
  • 50 Day Moving Average: $32.07
  • 200 Day Moving Average: $31.25
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $917.77M
  • Current Quarter EPS Consensus Estimate: $-2.35 EPS
Additional Links:
Editas Medicine (NASDAQ:EDIT) Chart for Sunday, June, 26, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha